Carmen Santander

585 total citations
19 papers, 172 citations indexed

About

Carmen Santander is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Carmen Santander has authored 19 papers receiving a total of 172 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 8 papers in Surgery and 7 papers in Oncology. Recurrent topics in Carmen Santander's work include Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Bladder and Urothelial Cancer Treatments (4 papers). Carmen Santander is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Bladder and Urothelial Cancer Treatments (4 papers). Carmen Santander collaborates with scholars based in Spain, Chile and United Kingdom. Carmen Santander's co-authors include Jorge Bravo, Aranzazu González del Alba, Josefa Terrasa, Javier Sastre, Daniel Castellano, Begoña Mellado, Marta López Brea, Xavier García del Muro, Jorge Aparicio and A. Sáenz and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Obesity Surgery.

In The Last Decade

Carmen Santander

17 papers receiving 170 citations

Peers

Countries citing papers authored by Carmen Santander

Since Specialization

Citations

This map shows the geographic impact of Carmen Santander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmen Santander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmen Santander more than expected).

Fields of papers citing papers by Carmen Santander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmen Santander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmen Santander. The network helps show where Carmen Santander may publish in the future.

Co-authorship network of co-authors of Carmen Santander

This figure shows the co-authorship network connecting the top 25 collaborators of Carmen Santander. A scholar is included among the top collaborators of Carmen Santander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmen Santander. Carmen Santander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Avelumab maintenance in advanced urothelial carcinoma: real-world data from Northern Spain (AVEBLADDER study) 2025 ·Clinical & Translational Oncology ·(unknown), Mireia Peláez, (unknown), (unknown), (unknown), (unknown), Carmen Santander, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Núria Laínez, (unknown), (unknown), Ricardo Fernández, (unknown), (unknown)	0
2	Real-world data (RWD) with avelumab in patients (pts) with locally advanced or metastatic urothelial cancer (la-mUC): The AVEBLADDER study. 2024 ·Journal of Clinical Oncology ·(unknown), Mireia Peláez, (unknown), (unknown), (unknown), (unknown), Carmen Santander, (unknown), (unknown), (unknown), Carlos Álvarez-Fernández, (unknown), (unknown), Núria Laínez, (unknown), (unknown), Ricardo Fernández, (unknown), (unknown)	1
3	Atezolizumab for locally advanced/metastatic urothelial carcinoma within the compassionate use program in Spain: The IMcompass study. 2022 ·Journal of Clinical Oncology ·(unknown), José Luis Perez‐Gracia, Jóse Ángel Arranz Arija, Carlos Álvarez-Fernández, (unknown), Ángel Rodríguez, Sergio Vázquez‐Estévez, J.M. Jurado, Carmen Santander, Teresa Bonfill, (unknown), Sara Ramírez, (unknown), (unknown), (unknown), (unknown), Javier Puente	1
4	Randomized phase II study of docetaxel (D) + abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial. 2020 ·Journal of Clinical Oncology ·Miguel Á. Climent Durán, Albert Font, Ignacio Durán, Javier Puente, Daniel Castellano, M.I. Sáez, (unknown), Carmen Santander, Jóse Ángel Arranz Arija, Aranzazu González del Alba, (unknown), Emilio Esteban, Teresa Alonso Gordoa, Pablo Maroto, (unknown), Javier Cassinello, Begoña P. Valderrama, María José Juan-Fita, Begoña Mellado, (unknown)	1
5	A phase II multicenter biomarker trial to study the predictive value of TMPRSS2-ERG before enzalutamide treatment in chemo-naïve metastatic castration-resistant prostate cancer. 2019 ·Journal of Clinical Oncology ·Enrique Grande, (unknown), Daniel Wetterskog, Albert Font Pous, Sergio Vázquez‐Estévez, Aranzazu González del Alba, Begoña Mellado, (unknown), María José Méndez-Vidal, Miguel Ángel Climent, Ignacio Durán, (unknown), (unknown), Carmen Santander, M.I. Sáez, Javier Puente, Elena Castro, Daniel Castellano, Gerhardt Attard, Enrique González‐Billalabeitia, (unknown)	2
6	SPAZO2 (SOGUG): Comparative effectiveness of pazopanib in metastatic renal carcinoma (mRC): Ineligible (I) vs eligible (E) patients for clinical trials 2017 ·Annals of Oncology ·(unknown), Begoña P. Valderrama, (unknown), Isabel Chirivella González, (unknown), J.P. Maroto Rey, (unknown), Miguel Á. Climent Durán, (unknown), Jorge A. García, Alejo Rodríguez‐Vida, Ricardo Fernández, Carmen Santander, (unknown), (unknown), (unknown), (unknown), (unknown), Sara Ramírez, (unknown)	2
7	Association of CTC detection by AdnaTest with outcome on enzalutamide in chemotherapy-naïve castration-resistant prostate cancer: Exploratory results from PREMIERE—A SOGUG trial. 2017 ·Journal of Clinical Oncology ·Albert Font Pous, Sergio Vázquez‐Estévez, Aranzazu González del Alba, Begoña Mellado, (unknown), María José Méndez, María José Juan-Fita, (unknown), Begoña Pérez‐Valderrama, Enrique Gallardo, Carmen Santander, M.I. Sáez, Javier Puente, Teresa Alonso, (unknown), Alberto Martínez, (unknown), Enrique Grande, Enrique González‐Billalabeitia, Daniel Castellano	1
8	Early responses to enzalutamide in AR-V7 positive first line metastatic castration-resistant prostate cancer (mCRPC). A prospective SOGUG clinical trial: The PREMIERE study 2016 ·Annals of Oncology ·Enrique Grande, (unknown), Albert Font, (unknown), Begoña Mellado, (unknown), (unknown), José A. Martínez-Climent, Aranzazu González del Alba, Enrique Gallardo, (unknown), Carmen Santander, M.I. Sáez, Ignacio Durán, Javier Puente, Teresa Alonso Gordoa, (unknown), Álvaro Martínez, Daniel Castellano, Enrique González‐Billalabeitia	4
9	Impact of previous abiraterone acetate treatment in docetaxel safety profile: Preliminary results of the randomized phase II ABIDO-SOGUG trial. 2016 ·Journal of Clinical Oncology ·Ignacio Durán, Miguel Ángel Climent, Albert Font, M.I. Sáez, Daniel Castellano, María José Méndez-Vidal, Javier Puente, Carmen Santander, Jóse Ángel Arranz Arija, Enrique Grande, (unknown), (unknown), Aranzazu González del Alba, Javier Cassinello, Pablo Maroto, Emilio Esteban, Begoña Pérez‐Valderrama, María José Juan-Fita, (unknown), Begoña Mellado, (unknown)	1
10	Randomized phase II study of abiraterone acetate (AA) maintenance in combination with docetaxel after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): Preliminary safety results of first line AA treatment—ABIDO-SOGUG Trial. 2015 ·Journal of Clinical Oncology ·Ignacio Durán, Enrique Grande, Daniel Castellano, Albert Font, M.I. Sáez, Javier Puente, Carmen Santander, María José Méndez-Vidal, Jóse Ángel Arranz Arija, Begoña Mellado, (unknown), Emilio Esteban, Aranzazu González del Alba, (unknown), Alfonso Gómez de Liaño, Javier Cassinello, Miguel Ángel Climent, (unknown)	1
11	Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy: PREMIERE-SOGUG Trial. 2015 ·Journal of Clinical Oncology ·Enrique Grande, Enrique González‐Billalabeitia, Ignacio Durán, Carmen Santander, (unknown), Aranzazu González del Alba, Javier Puente, (unknown), Albert Font, Miguel Ángel Climent, Luis León‐Mateos, M.I. Sáez, Begoña Mellado, María José Méndez-Vidal, Sergio Vázquez‐Estévez, (unknown), (unknown), Teresa Alonso, Daniel Castellano	1
12	Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base 2014 ·Clinical & Translational Oncology ·(unknown), Regina Gironés, Jorge Aparicio, (unknown), J. R. Germa-Lluch, Xavier García del Muro, Sergio Vázquez‐Estévez, A. Sáenz, Javier Sastre, (unknown), Enrique Gallardo, Enrique González‐Billalabeitia, (unknown), Josefa Terrasa, (unknown), Carmen Santander, (unknown), (unknown), (unknown), Marta López Brea, Pablo Maroto	15
13	Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma 2014 ·Cancer Chemotherapy and Pharmacology ·Xavier García del Muro, Enrique Gallardo, Iciar Garcı́a Carbonero, Núria Laínez, María José Méndez, Pablo Maroto, María Ochoa de Olza, Javier Puente, Gaspar Reynés, José Rubio, Carmen Santander, Cristina Suárez, Sergio Vázquez‐Estévez, Daniel Castellano	0
14	Correlation Between Age and Weight Loss after Bariatric Surgery 2013 ·Obesity Surgery ·(unknown), Carmen Santander, (unknown), Jorge Bravo	131
15	Vinflunine (VFL) as second-line chemotherapy for patients with transitional cell carcinoma of the urothelium (TCCU): A multicenter retrospective study. 2013 ·Journal of Clinical Oncology ·Guillermo de Velasco, Isabel Chirivella, (unknown), (unknown), Álvaro Pinto, (unknown), Carmen Santander, Daniel Castellano	3
16	Comparing diagnosis, management, and outcomes of synchronous versus metacrhonus brain metastases from testicular germ cell tumors (TGCT): Multinstitutional experience from the Spanish Germ Cell Cancer Group (SGCCG). 2013 ·Journal of Clinical Oncology ·Jorge Aparicio, Regina Gironés, (unknown), J. R. Germa-Lluch, Sergio Vázquez‐Estévez, A. Sáenz, Javier Sastre, Jóse Ángel Arranz Arija, Enrique Gallardo, Enrique González‐Billalabeitia, (unknown), Josefa Terrasa, Ana Lluch Hernández, Carmen Santander, (unknown), (unknown), (unknown), Marta López Brea, Pablo Maroto, (unknown)	2
17	Safety of sunitinib in renal cell carcinoma 2012 ·European Journal of Hospital Pharmacy ·(unknown), (unknown), Carmen Santander, (unknown), (unknown), (unknown)	1
18	Macromastia gestacional unilateral 2008 ·Revista Chilena de Cirugía ·(unknown), (unknown), (unknown), Roberto Cândia, (unknown), Carmen Santander	1
19	Phase II Trial of Oral Tegafur and Folinic Acid with Mitoxantrone as First-Line Regimen in Patients with Metastatic Breast Cancer 1996 ·Tumori Journal ·Vicente Alonso, Carmen Santander, Jesús Florián, (unknown), Dolores Isla, P. Escudero, A. Sáenz, A. Trés	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact